Conference Programme

You will find the preliminary programme of the conference on February, 24th here. 

Time Title
09:00 – 09:30 Registration
09:30 – 09:45 Welcome address
Sir Sebastian Wood KCMG, British Ambassador to Germany
Keynote Session
09:45 – 10:10 Keynote: Why thinking about novel antimicrobials
Lord Jim O'Neill, AMR review, UK (requested)
10:10 – 10:30 Market perspective: Obstacles and opportunities in developing new approaches to fight AMR
David Findlay, Deputy Coordinator Drive-AB/GSK, UK
10:30 – 10:50

Technology overview: Company strategies in microbial defence – beyond common antibiotic strategies
Marcin Mankowski, CMO, Allecra, GER

10:50 – 11:10 Coffee Break
Session "Market access in the era of AMR - from idea to product"

Session “SMEs to tackle AMR”

Chair: Philippe Villain-Guillot, CEO, Nosopharm

- Philippe Villain-Guillot, CEO,
Nosopharm, F
- Leonie de Best, CBO, Madam Therapeutics, NL
- Blueberry Therapeutics, UK (requested)
- NovaBiotics, UK (requested)
- PhicoTherapeutics, UK (requested)

11:10 – 11:30 IP & Regulation: Patent strategies to meet the challenge
of AMR
Ute Kilger, Partner, Boehmert & Boehmert, GER
11:30 – 11:50 Clinical perspective: Clinical studies for antimicrobials
Sharp Clinical Services, USA (requested)
11:50 – 12:10 Market access: Fast track conditions and approval of new
drugs in Europe
12:10 – 12:30 Economics: Distribution strategies, funding and re-imbursement models for antimicrobials
Matthew Taylor, Director, York Health Economics Consortium, University of York, UK (requested)
12:30 – 13:30 Lunch Break
Session “How to create a business case with antimicrobials” Session: Think beyond – technology highlights from academic research

Chair: Andrew Ullmann, University of Würzburg

- Rob Lavigne, KU Leuven, B (requested)
- Andreas Peschel, University of
Tübingen, D (requested)

13:30 – 13:50 Public-private partnerships to accelerate the devlopment of antimicrobial drugs
Peter Jackson, steering group chairman, AMR centre, UK (requested)
13:50 – 14:10 The SME perspective
Marc Gitzinger, CEO, BioVersys, CH
14:10 – 14:30 Convincing investors of novel antimicrobials
Neil Murray, CEO, RedX Pharma, UK (requested)
14:30 – 15:30

Technology Highlights
- Rasmus Toft-Kehler, CEO, AntibioTx, DK
- Marc Lemonnier, CEO, Antabio, F
- Jeff Wager, CEO, EnBiotix, USA/GER (requested)
- Glenn Dale, Head of Antibiotics Development, Polyphor, CH (requested)

15:30 – 16:00 Coffee Break
Session “Start-up competition & investors talk”
16:00 – 16:20

Investors talk – Panel Discussion: Developing new antimicrobial agents - a business case for start-ups?
Holger Reithinger, Partner, Forbion Capital Partners, GER/NL
Marc Gitzinger, CEO, BioVersys, CH
Rasmus Toft-Kehler, CEO, AntibioTx, DK
Olivier Litzka, Partner, Edmond de Rothschild, F
Patrick Burgermeister, Partner, BioMedPartners AG, CH

16:20 – 17:20

Start-up pitch: Start-up presentations and award
Auspherix, UK (requested)
Centauri Therapeutics, UK (requested)
Eligo Biosciences, F (requested)
Immunethep, P
Oxford Antibiotics, UK (requested)
QureTech Bio, S

17:20 – 17:40 Open discussion and wrap-up: The future of antiinfective R&D
17:40 – 19:00 Networking & reception

Moderator: Peter West, CEO, Academy of Infection Management (AIM)